“Has anyone rebutted Midas letter analysis. Of what he calls teh downside risk to cydy?”

Don’t waste your time. CYDY has been accepting poor financing deals for years because they’re a small biotech without revenue. This Midas letter is pointing out the obvious, what we all as investors already know.